Dr. Li Fangfei and Dr. Liang Chao in CCIR attended the Hong Kong Chinese Medicine Pharmacology Society Founding Congress and Symposium in Ningbo on September 22, 2017. In the symposium, Dr. Li Fangfei was invited to present her work entitled “Toward the next generation of smart anti-tumor drugs: a highly water-soluble nucleolin aptamer-paclitaxel conjugate with a serum-stable linker for tumor-specific targeting in ovarian cancer”, and Dr. Liang Chao was invited to introduced his study entitled “Inhibition of osteoblastic Smurf1 promotes bone formation in distinctive individuals with age-related osteoporosis”.